Haploidentical Transplant with Post-Transplant Cyclophosphamide for CGD

Phase 2, open-label, single-arm trial of cyclophosphamide in chronic granulomatous disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Efficacy of This Allogeneic Transplant Approach in Reconstituting Normal Hematopoiesis and Reversing the Clinical Phenotype of CGD at 5 years. Started Oct 2014; status: terminated.